I Ask This Of You!

I have Parkinson's diseases and thought it would be nice to have a place where the contents of updated news is found in one place. That is why I began this blog.

I copy news articles pertaining to research, news and information for Parkinson's disease, Dementia, the Brain, Depression and Parkinson's with Dystonia. I also post about Fundraising for Parkinson's disease and events. I try to be up-to-date as possible.

I am not responsible for it's contents. I am just a copier of information searched on the computer. Please understand the copies are just that, copies and at times, I am unable to enlarge the wording or keep it uniformed as I wish.

This is for you to read and to always keep an open mind.

Please discuss this with your doctor, should you have any questions, or concerns.

Never do anything without talking to your doctor. I do not make any money from this website. I volunteer my time to help all of us to be informed. I will not accept any information about Herbal treatments curing Parkinson's, dementia and etc. It will go into Spam.

This is a free site for all with no advertisements.

Thank you for visiting!

Wednesday, June 28, 2017

Parkinson's Disease Patients are First to be Treated With Elekta's New Leksell Vantage Stereotactic System

June 28, 2017

Clinicians report improved surgical workflow, patient comfort 
and accuracy in stereotactic imaging and treatment

Elekta (EKTA-B.ST) today announced that its Leksell®Vantage™ Stereotactic System is now in clinical use at three European centers. The first surgeries were performed on a patient with Parkinson's disease at the National Hospital for Neurology and Neurosurgery, Queen Square (London, England) and a patient with Parkinson's disease at Karolinska University Hospital (Stockholm, Sweden). Both sites have now treated several patients.
Subsequent to these first two procedures, Academisch Medisch Centrum (Amsterdam, the Netherlands) has also initiated clinical use of Vantage. Additionally, Hopital La Timone (Marseille, France) has completed training on Vantage and is commencing system utilization. 
Leksell Vantage is Elekta's next-generation system for target localization and coordinate referencing during stereotactic neurosurgical procedures. Both patients were successfully implanted with deep brain stimulation electrodes, a procedure that requires precision targeting.  
Stereotactic neurosurgery is a minimally-invasive approach to precisely localize and treat specific regions in the brain while sparing surrounding healthy tissue. This surgery has been used successfully for decades to treat a variety of brain and neurologic conditions, including brain cancer, non-malignant tumors, essential tremor and Parkinson's disease. Stereotactic neurosurgery is also used to make small controlled lesions of brain pathologies or to facilitate drug delivery to regions of the brain that are challenging to access. Immobilization of the patient's head during neuroimaging and subsequent neurosurgical procedures is essential for accurate targeting and optimal clinical safety and efficacy. 
Leksell Vantage Stereotactic System was designed with the patient in mind and to meet the most exacting demands of today's clinicians, enabling a smooth workflow and offering a range of benefits, including shorter treatment times, non-metallic MRI-compatible accessories, intuitive setup and workflow enhancements.
"Our first experiences with the Leksell Vantage Stereotactic System indicate the potential for obtaining images with more anatomical detail," said Ludvic Zrinzo, MD, PhD, FRCS, Senior Lecturer and Consultant in Neurosurgery at National Hospital for Neurology and Neurosurgery, Queen Square, London. "The 'open face' design is an advantage in both awake and asleep surgery and the updated design provides a more patient and user friendly system."
Prof. Lars Leksell, the founder of Elekta, developed his innovative center-of-arc-based stereotactic system during his tenure as professor and chairman of neurosurgery at Karolinska University Hospital. This system ultimately evolved into a user-friendly and world-renowned stereotactic system that has helped improve the care and outcomes for patients around the world.
"Elekta is proud to report that the first successful surgeries with the Leksell Vantage System have been performed at these prestigious and experienced centers of neurosurgery. Vantage is the most current representation of our legacy of innovation and it reflects our ongoing commitment to working closely with clinicians to develop devices and software that enable them to provide optimal care to all their patients," said Jesper Söderqvist, Vice President Neuro Portfolio at Elekta. 
For more information about Leksell Vantage, stop by Elekta booth 11-13 at the 17th Quadrennial Meeting of the World Society for Stereotactic and Functional Neurosurgery (WSSFN) or visit
For further information, please contact:
Gert van Santen, 
Group Vice President Corporate Communications,
Elekta AB
Tel: +31-653-561-242
Time zone: CET: Central European Time
Raven Canzeri, 
Global Public Relations Manager,
Tel: +1-770-670-2524
Time zone: ET: Eastern Time
This information was brought to you by Cision


Elekta Highlights Leksell Vantage System for Stereotactic Neurosurgery at AANS 2017
New studies also reinforce Gamma Knife as a clinically effective, minimally invasive approach to treating cancer, noncancerous brain tumors and neurological conditions

April 24, 2017 — Elekta announced that its Leksell Vantage Stereotactic System, will be highlighted at the American Association of Neurological Surgeons (AANS) Annual Meeting, April 22-26 in Los Angeles. 

Leksell Vantage is the company's next-generation system for target localization and coordinate referencing for precision neurosurgery. The system’s head frame is constructed of a novel epoxy composite and is designed to improve imaging quality, speed and patient comfort in neurosurgery procedures. 
Vantage received CE Mark clearance in March 2017 and will be used in April in clinical practice for the first time in Europe at four centers, including: 
University Hospital La Timone (Marseilles, France); 
The Academic Medical Center (Amsterdam, the Netherlands); 
The National Hospital for Neurology and Neurosurgery, Queens Square (London, England); and Karolinska University Hospital (Stockholm, Sweden). 
The system is currently pending 510(k) clearance with the U.S. Food and Drug Administration (FDA).

 In addition to Vantage, Elekta will highlight its Leksell Gamma Knife radiosurgery system. The system will be discussed in more than 15 scientific presentations at AANS, including: 

Abstract #1837: "Stereotactic Radiosurgery for Intractable Tremor-Dominant Parkinson Disease"; Ajay Niranjan, M.D., MBA, associate professor, neurological surgery, director UPMC Brain Mapping Center and associate director, Center for Image-Guided Neurosurgery at the University of Pittsburgh Medical Center. This study analyzed the outcomes of 33 patients who received Gamma Knife radiosurgery to treat medically refractory Parkinson's disease (PD) tremor. At a mean follow-up period of 23 months, 23 patients (70 percent) had complete or nearly complete tremor arrest, and nine (27.2 percent) experienced tremor arrest and improved ability to write, draw and drink fluids. Tremor resolution was maintained in 96.8 percent of individuals at last follow-up visit. Study investigators concluded that Gamma Knife is a safe and effective treatment for medically refractory PD tremor, especially in the elderly or individuals who are not suitable candidates for deep brain stimulation or thermal therapy. 

Abstract #2022: "Direct Comparison of Microsurgery and Gamma Knife Radiosurgery on Small Size Meningiomas"; Shyamal C. Bir, M.D., Ph.D., post-doctoral fellow, Louisiana State University Health Sciences Center Shreveport, and Anil Nanda, M.D., MPH, professor and chairman of the Department of Neurosurgery at LSU Health Sciences Center at Shreveport. In this study, investigators performed a retrospective review of 90 consecutive patients with small intracranial meningiomas (benign tumors arising from the membranes covering the brain and spinal cord) undergoing microsurgery (n= 31) or Gamma Knife radiosurgery (n=59). Study results demonstrated that Gamma Knife radiosurgery was associated with significantly higher local control of tumor growth compared with microsurgical resection at five and 10 years (p=0.02 and p=0.003, respectively). In addition, the median recurrence free survival period was also significantly higher in the Gamma Knife group (p=0.04). 

Additional data presented during the conference confirmed that Leksell Gamma Knife was the most frequently mentioned stereotactic radiosurgery (SRS) system in a comprehensive clinical literature review with 11,638 citations out of 13,539 articles retrieved. Gamma Knife was also the most frequently cited SRS system in neurosurgical indications, including brain metastases (n=1037), arteriovenous malformation (n=734) and spinal metastases (n=184). For more information:

No comments:

Post a Comment